Vigil Neuroscience provides update on Phase 2 IGNITE trial of iluzanebart
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 04 2025
0mins
Clinical Trial Update: Vigil Neuroscience reported on the Phase 2 IGNITE trial of iluzanebart, a TREM2 agonist for treating adult-onset leukoencephalopathy, showing favorable safety but no efficacy in ALSP patients.
Study Discontinuation: Due to the lack of beneficial effects on biomarkers or clinical endpoints, the long-term extension study of the Phase 2 trial will be discontinued.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
